Differentiation of skeletal osteogenic progenitor cells to osteoblasts with 3,4-diarylbenzopyran based amide derivatives: Novel osteogenic agents.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  European journal of medicinal chemistry

• Publication date

  2016-10-04

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ejmech.2016.05.023PMID 27236065
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Induction of targeted osteogenesis with 3-aryl-2H-benzopyrans and 3-aryl-3H-benzopyrans: Novel osteogenic agents.

  2016cited by this paper
• Estrogen and bone health in men and women.

  2015cited by this paper
• Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis

  2015cited by this paper
• Osteoporosis and Lifestyle.

  2015cited by this paper
• Minireview: nuclear receptor regulation of osteoclast and bone remodeling.

  2015cited by this paper
• Bone Health and Osteoporosis.

  2015cited by this paper
• Bone morphogenetic protein signaling in bone homeostasis.

  2015cited by this paper
• Bone biology, signaling pathways, and therapeutic targets for osteoporosis.

  2015cited by this paper
• The Osteoporosis Treatment Gap

  2014cited by this paper
• Osteoporosis: A Lifecourse Approach

  2014cited by this paper
• Design and synthesis of ERα/ERβ selective coumarin and chromene derivatives as potential anti-breast cancer and anti-osteoporotic agents

  2014cited by this paper
• Novel daidzein analogs enhance osteogenic activity of bone marrow-derived mesenchymal stem cells and adipose-derived stromal/stem cells through estrogen receptor dependent and independent mechanisms

  2014cited by this paper
• Formononetin attenuates osteoclastogenesis via suppressing the RANKL-induced activation of NF-κB, c-Fos, and nuclear factor of activated T-cells cytoplasmic 1 signaling pathway.

  2014cited by this paper
• Design, synthesis, and osteogenic activity of daidzein analogs on human mesenchymal stem cells.

  2014cited by this paper
• Isoformononetin, a methoxydaidzein present in medicinal plants, reverses bone loss in osteopenic rats and exerts bone anabolic action by preventing osteoblast apoptosis.

  2013cited by this paper
• New insights into osteoclastogenic signaling mechanisms.

  2012cited by this paper
• New understanding and treatments for osteoporosis

  2012cited by this paper
• Medicarpin, a legume phytoalexin, stimulates osteoblast differentiation and promotes peak bone mass achievement in rats: evidence for estrogen receptor β-mediated osteogenic action of medicarpin.

  2012cited by this paper
• Estrogen and the skeleton.

  2012cited by this paper
• Synthetic analogs of daidzein, having more potent osteoblast stimulating effect.

  2011cited by this paper
• Evaluation of bone quality and quantity in osteoporotic mice--the effects of genistein and equol.

  2010cited by this paper
• Synthesis and anti-osteoporotic evaluation of certain 3-amino-2-hydroxypropoxyisoflavone derivatives.

  2009cited by this paper
• Association between serum osteocalcin and markers of metabolic phenotype.

  2009cited by this paper
• Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

  2008cited by this paper
• Normal bone anatomy and physiology.

  2008cited by this paper
• Safety evaluation of a standardized phytochemical composition extracted from Bacopa monnieri in Sprague--Dawley rats.

  2007cited by this paper
• Signaling and transcriptional regulation in osteoblast commitment and differentiation.

  2007cited by this paper
• Osteoclast-derived activity in the coupling of bone formation to resorption.

  2005cited by this paper
• Genistein derivatives as selective estrogen receptor modulators: sonochemical synthesis and in vivo anti-osteoporotic action.

  2005cited by this paper
• Effect of ipriflavone and estrogen on the differentiation and proliferation of osteogenic cells

  2005cited by this paper
• Anabolic Therapy for Osteoporosis

  2005cited by this paper
• Equol, a metabolite of daidzein, inhibits bone loss in ovariectomized mice.

  2004cited by this paper
• Synthesis, pharmacological evaluation, and structure-activity relationships of benzopyran derivatives with potent SERM activity.

  2004cited by this paper
• Equol, a natural estrogenic metabolite from soy isoflavones: convenient preparation and resolution of R- and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta.

  2004cited by this paper
• Bone Morphogenetic Proteins

  2004cited by this paper
• Daidzein enhances osteoblast growth that may be mediated by increased bone morphogenetic protein (BMP) production.

  2003cited by this paper
• Targeted and nontargeted remodeling.

  2002cited by this paper
• Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression.

  2002cited by this paper
• The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones.

  2002cited by this paper
• Estrogen reduces the depth of resorption pits by disturbing the organic bone matrix degradation activity of mature osteoclasts.

  2001cited by this paper
• Hormone replacement therapy and the endometrium

  2001cited by this paper
• Minireview: the OPG/RANKL/RANK system.

  2001cited by this paper
• 17β-Estradiol Stimulates Expression of Osteoprotegerin by a Mouse Stromal Cell Line, ST-2, via Estrogen Receptor-α.

  2001cited by this paper
• 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha.

  2001cited by this paper
• Structural insights into the mode of action of a pure antiestrogen.

  2001cited by this paper
• Clinical review 123: Anabolic therapy for osteoporosis.

  2001cited by this paper
• Novel Basic Isoflavones as Inhibitors of Bone Resorption

  2001cited by this paper
• Daidzein is more efficient than genistein in preventing ovariectomy-induced bone loss in rats.

  2000cited by this paper
• Tissue Engineers Build New Bone

  2000cited by this paper
• Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis.

  2000cited by this paper
• Bone Health in The Balance

  2000cited by this paper
• Therapeutic approaches to bone diseases.

  2000cited by this paper
• Stimulatory effect of Daidzein in osteoblastic MC3T3-E1 cells.

  2000cited by this paper
• Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells.

  1999cited by this paper
• Emerging therapies for the prevention or treatment of postmenopausal osteoporosis.

  1999cited by this paper
• Inhibitory effect of genistein on bone resorption in tissue culture.

  1998cited by this paper
• Biochemical markers of bone metabolism: an overview.

  1997cited by this paper
• Differential expression of estrogen receptors alpha and beta mRNA during differentiation of human osteoblast SV-HFO cells.

  1997cited by this paper
• Differential Expression of Estrogen Receptors α and β mRNA During Differentiation of Human Osteoblast SV-HFO Cells.

  1997cited by this paper
• The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

  1995cited by this paper
• Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis.

  1993cited by this paper
• 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens.

  1992cited by this paper
• Increased osteoclast development after estrogen loss: mediation by interleukin-6.

  1992cited by this paper
• Increased osteoclast development after estrogen loss: mediation by interleukin-6

  1992cited by this paper
• Bone morphogenetic protein-2 stimulates alkaline phosphatase activity and collagen synthesis in cultured osteoblastic cells, MC3T3-E1.

  1991cited by this paper
• Structure-activity relationship of antiestrogens. Phenolic analogues of 2,3-diaryl-2H-1-benzopyrans.

  1990cited by this paper
• Metabolic and clinical effects of ipriflavone in established post-menopausal osteoporosis.

  1989cited by this paper
• Enhanced osteoblast proliferation and collagen gene expression by estradiol.

  1988cited by this paper
• Novel regulators of bone formation: molecular clones and activities.

  1988cited by this paper
• Antifertility agents. 12. Structure-activity relationship of 3,4-diphenylchromenes and -chromans.

  1976cited by this paper
• Printed in U.S.A. Copyright © 2001 by The Endocrine Society Estrogen Reduces the Depth of Resorption Pits by Disturbing the Organic Bone Matrix Degradation Activity of Mature Osteoclasts

  year unknowncited by this paper

• From biosynthesis to therapeutics: A comprehensive review on varied functions of estrogen and selective estrogen receptor modulators

  2025cites this paper
• Myosin heavy chain-derived peptide of Gadus morhua promotes proliferation and differentiation in osteoblasts and bone formation and maintains bone homeostasis in ovariectomized mice.

  2023cites this paper
• Label-free quantitative proteomic analysis of ascorbic acid-induced differentially expressed osteoblast-related proteins in dental pulp stem cells from deciduous and permanent teeth.

  2022cites this paper
• Design, synthesis and biological evaluation of new quinazolinone-benzopyran-indole hybrid compounds promoting osteogenesis through BMP2 upregulation.

  2022cites this paper
• Benzofuran pyran hybrid prevents glucocorticoid induced osteoporosis in mice via modulation of canonical Wnt/β-catenin signaling

  2022cites this paper
• Diastereoselective synthesis of spiro[chromane-3,3'-indolines] and spiro[chromane-3,2'-indenes] via DBU promoted formal [4 + 2]cycloaddition reaction

  2021cites this paper
• Synthesis and biological activities of drugs for the treatment of osteoporosis.

  2020cites this paper
• Catalytic asymmetric [4+2] cycloaddition of 1-((2-aryl)vinyl)naphthalen-2-ols with in situ generated ortho-quinone methides for the synthesis of polysubstituted chromanes.

  2019cites this paper
• Phosphoric Acid Catalyzed Aldehyde Addition to in Situ Generated o-Quinone Methides: An Enantio- and Diastereoselective Entry toward cis-3,4-Diaryl Dihydrocoumarins.

  2018cites this paper
• Synthesis and study of benzofuran-pyran analogs as BMP-2 targeted osteogenic agents.

  2018cites this paper
• Benzofuran-pyran hybrids: A new class of potential bone anabolic agents.

  2018cites this paper
• Changes in related circular RNAs following ERβ knockdown and the relationship to rBMSC osteogenesis.

  2017cites this paper
• Synthesis of 3,5-dihydroxy-7,8-dimethoxy-2-(4-methoxyphenyl)benzopyran-4-one derivatives as anticancer agents.

  2016cites this paper